In MM patients, after treatment with lenalidomide, OPG levels were significantly higher than baseline (P < 0, 05), whereas RANKL production was inhibited, so lenalidomide has been confirmed to reduce the serum markers of bone lytic disease. The gene discussed is TNFRSF11B; the disease is Miyoshi myopathy.